Globus Medical (GMED) Receives Price Target

Globus Medical (GMED) : 8 investment research analysts covering Globus Medical (GMED) have an average price target of $26.75 for the near short term. The highest target price given by the Brokerage Firm to the stock is $33 and the lowest target is $23 for the short term. Analysts expect the variance to be within $3.24 of the average price.

Globus Medical (GMED) : Zacks Investment Research ranks Globus Medical (GMED) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 11 research analysts is 2.18, which indicates as a Buy.


Also, In the latest statement by the brokerage house, Morgan Stanley maintains its outlook on Globus Medical (NYSE:GMED). The current rating of the shares is Equal-weight, according to the research report released by the firm. The brokerage firm lowers the price target from $28 per share to $25 per share. The rating by the firm was issued on July 28, 2016.

Globus Medical (NYSE:GMED): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.22 and $22.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.57. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.46, notching a gain of 0.99% for the day. The total traded volume was 401,115 . The stock had closed at $23.23 on the previous day.

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.